Date of genomic study consent for CGP was the index date for overall survival, and initial clinic visit was the index date for the No CGP group. For both cohorts, this represented the start of the process for identifying investigative treatment options. As the cohorts reflected successive time periods, potential follow-up time was systematically different. All patients had a minimum of 12 months’ follow up and survival analysis was censored at 18 months to reduce discrepancy in time at risk across cohorts. Unadjusted and IPTW adjusted Kaplan-Meier survival curves were used to generate plots and estimate survival probabilities, unadjusted and IPTW adjusted hazard ratios (HRs) were estimated using Cox proportional hazards regression. It was calculated that a HR of 0.65 could be detected with 80% power at a 5% significance level with a sample of 260 and a 65% event rate [30 ]. The proportional hazards assumption was assessed through significance testing of scaled Schoenfeld residuals. Robust variance estimates were used in adjusted analyses to account for the dependency induced through weighting subjects [31 (link)]. Data cleaning was performed in Stata/IC version 14.2 and analysis and graphics performed using R statistical software, version 3.6.3.